A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study (CROSBI ID 214904)
Prilog u časopisu | izvorni znanstveni rad
Podaci o odgovornosti
Kutsal, Yesim Gokce ; Eskiyurt, Nurten ; Irdesel, Jale ; Sepici, Vesile ; Ugurlu, Hatice ; Kirazli, Yesim ; Ardic, Fusun ; Korsic, Mirko ; Vlak, Tonko ; Grlickov, Mane ; Markovic Temelkova, Snezana ; Lazarov, Miroslav ; Pilipovic, Nada ; Popovic, Vera ; Dimic, Aleksandar ; Kovacev, Branka ; Ruci, Dorina ; Tafaj, Argjend ; Kucukalic Selimovic, Elma ; Avdic, Dijana ; Seleskovic, Hajrija ; Pejicic, Snjezana ; Butun, Bulent ; Akyuz, Gulseren ; Cerrahoglu, Lale ; Faruk Sendur, Omer ; Yalcin, Peyman ; Oncel, Sema ; Saridogan, Merih ; Sarpel, Tunay ; Tosun, Mehmet ; Senel, Kazim ; Gursoy, Savas ; Canturk, Ferhan ; Demir, Huseyin ; Miskic, Blazenka ; Krpan, Dalibor ; Skreb38, Franjo ; Grazio, Simeon ; Crncevic Orlic, Zeljka ; Ozdener, Fatih ; Oncel, Hakan
engleski
A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study
A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0 - 100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to- treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p < 0.001). Decreases in scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non- gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment.
Bisphosphonate ; Compliance ; Ibandronate ; Postmenopausal Osteoporosis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
